Composition for target-specific photothermal therapy

Abstract

Provided are a composition for target-specific photothermal therapy and a method of photothermal therapy using the composition and more particularly, a method of photothermal therapy for selectively killing inflammatory cells by using the composition for target-specific photothermal therapy comprising carbon nanotubes coated with dextran. According to the present invention, the composition for photothermal therapy comprising the carbon nanotubes coated with dextran is absorbed only into desired target cells, i.e., inflammatory cells, and causes thermotherapeutic action through light irradiated from an external light source, while not damaging cells except for inflammatory cells. The method of photothermal therapy using the composition for photothermal therapy has advantages of minimizing side effects and maximizing therapeutic effects.

Claims

1. A method of photothermal therapy for subjects, comprising: administering a composition consisting of (a) carbon nanotubes; and (b) dextran coated on the surface of the carbon nanotubes for target-specific photothermal therapy; and irradiating light, wherein a target of the target-specific photothermal therapy is macrophage cells which induce chronic inflammation in the subject, and the composition is administered with an amount resulting in a concentration in the subject of 0.05 mg/ml.

2. The method of photothermal therapy of claim 1, wherein the light is a near infrared (NIR) laser having a wavelength of 600 to 1000 nm.

3. A method of photothermal therapy of claim 1, wherein the carbon nanotubes are single walled carbon nanotubes (SWNTs).

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 is a graph illustrating a thermal energy emission behavior according to a concentration of dextran-coated SWNT according to Experimental Example 1.

(2) FIG. 2 is a graph illustrating verification of cytotoxicity of dextran-coated SWNT according to Experimental Example 2.

(3) FIG. 3 is a graph illustrating comparison of UV absorbance for each cell line treated with dextran-coated SWNT according to Experimental Example 3.

(4) FIG. 4 illustrates a transmission electron microscope (TEM) photograph of a NUFF1 cell line (A) and a Raw264.7 cell line (B) treated with the dextran-coated SWNT according to Experimental Example 3.

(5) FIG. 5 illustrates results of comparing cell killing effects according to a concentration of the dextran-coated SWNT according to Experimental Example 3 under a condition of NIR laser irradiation of Experimental Example 3.

(6) FIG. 6 illustrates results of comparing cell killing effects according to laser irradiation to the NUFF1 cell line and the Raw264.7 cell line treated with the dextran-coated SWNT according to Experimental Example 3.

(7) FIG. 7 illustrates results of NIR laser irradiation to the Raw264.7 cell line in the absence of the dextran-coated SWNT according to Experimental Example 3.

DESCRIPTION OF EXEMPLARY EMBODIMENTS

(8) Unless otherwise defined in the present specification, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. Various scientific events, including the terms included in the present specification, are well known and available in the art. Although any methods and materials similar or equivalent to those described in the present specification are found to be used in the practice or testing of the present application, some methods and materials have been described. It should not be understood that the present invention is limited to specific methods, protocols and reagents because the present invention may be used in various ways depending on the context used by those skilled in the art.

(9) As used in the present specification, the singular forms include plural objects unless the context clearly dictates otherwise. As used in the present specification, unless otherwise stated, or refers to and/or. Moreover, other forms, for example, have, comprising and configuring as well as the term including are not limited.

(10) The numerical range includes numerical values defined in the above range. All maximum numerical limitations given throughout the present specification include all lower numerical limitations, as the lower numerical limitations are explicitly stated. All minimum numerical limitations given throughout the present specification include all higher numerical limitations, as the higher numerical limitations are explicitly stated. All numerical limitations given throughout the present specification will include any better numerical range within the broader numerical range, as narrower numerical limitations are explicitly stated. The titles provided in the present specification should not be understood as limiting the following exemplary embodiments as a reference of the specification in various aspects or on the whole.

(11) The present invention provides a composition for target-specific photothermal therapy which has an effect on only cells to be treated without damaging other cells.

(12) The term photothermal therapy used in the present specification means a therapy method of accumulating a material generating heat by absorbing light in a location requiring hyperthermal therapy and irradiating light. Most of light in the infrared area is used and caused by aspects such as tissue permeability.

(13) The term carbon nanotube used in the present specification means a material which has a hexagonal honeycomb structure in which one carbon atom is sp2-bonded to three other carbon atoms and a diameter of several nanometers to tens micrometers. The carbon nanotubes have various types and are classified into single-walled carbon nanotube (SWNT) consisting of only one wall, double-walled carbon nanotube (DWNT) consisting of two walls, and multi-walled carbon nanotube (MWNT) consisting of two or more walls according to the number of walls which cover a longitudinal direction as an axis.

(14) The term dextran used in the present specification means soluble polysaccharide consisting of glucoses. The dextran is produced from sucrose by the action of microorganisms such as Leuconostoc mesenteroides and used as a plasma expander. It is known that the dextran has a characteristic uptaken by reacting with an inflammatory cell scavenger receptor.

(15) An exemplary embodiment of the present invention provides a composition for target-specific photothermal therapy, comprising: (a) carbon nanotubes; and (b) dextran coated on the surface of the carbon nanotubes.

(16) According to the present invention, the composition for photothermal therapy is specific to inflammatory cells.

(17) The term target-specific used in the present specification refers to a characteristic that the composition for photothermal therapy according to the present invention binds to the corresponding target or tissue in various kinds of targets or tissues present in a living body of the human or animals.

(18) The term inflammation used in the present specification refers to a pathological condition of abscesses formed by invasion of external infectious sources (bacteria, fungi, viruses, various kinds of allergens). As a mechanism of inflammation, it is known that vasodilatation, increased capillary permeability, and aggregation of macrophages into inflamed areas are caused by the release of histamine and kinin due to cellular damage, and as a result, increased blood flow, swelling, migration of immune cells and antibodies, pain, fever, etc. occur at the infected areas.

(19) The term macrophage used in the present specification refers to major cells responsible for innate immunity, and most of macrophages are fixed to the whole body, but some macrophages are present in a form of monocytes in the blood. The monocytes may be differentiated into dendritic cells or macrophages.

(20) According to the present invention, the composition for photothermal therapy is used for diagnosis or treatment of inflammatory cell-mediated diseases.

(21) The term inflammatory cell-mediated disease used in the present specification includes rheumatoid arthritis, ulcerative colitis, Crohn's disease, psoriasis, osteomyelitis, multiple sclerosis, atherosclerosis, pulmonary fibrosis, sarcoidosis (sarcomatosis), systemic sclerosis, graft versus host disease (GVHD) or chronic inflammation, but is not limited thereto.

(22) The term diagnosis used in the present specification is to identify the presence or characteristic of a pathological condition and may include determining whether the corresponding subject has recurrence, metastasis, drug reactivity, resistance, etc. after treatment of the inflammatory cell-mediated disease as well as identifying whether the inflammatory cell-mediated disease occurs according to the present invention.

(23) The term treatment used in the present specification refers to all activities in which symptoms of the inflammatory cell-mediated disease are improved or completely cured by the composition for photothermal therapy according to the present invention.

(24) Another exemplary embodiment of the present invention provides a method of photothermal therapy for subjects except for the human, comprising: administering a composition for target-specific photothermal therapy according to the present invention; and percutaneously irradiating light having a wavelength of 600 to 1000 nm.

(25) The term subject used in the present specification includes monkeys, dogs, goats, pigs or rats to which the composition for photothermal therapy according to the present invention is administered to improve the inflammatory cell mediated diseases, but is not limited thereto.

(26) The term administration used in the present specification refers to providing a predetermined composition for photothermal therapy according to the present invention to the subject by any appropriate method. The administration includes both oral administration and parenteral administration, but the composition is preferably administered in a parenteral manner. The parenteral administration includes, for example, intravenous injection, subcutaneous injection, muscle injection, intraperitoneal injection, transdermal administration, or intralesional injection, but is not limited thereto. An appropriate does of the composition for photothermal therapy according to the present invention varies depending on factors such as a formulation method, an administration method, age, weight, gender, and pathosis of a patient, food, an administration time, an administration route, an excretion rate and response sensitivity, and usually, skilled doctors may easily determine and prescribe an effective dose for desired treatment or prevention.

(27) According to the present invention, the light wavelength is in a range of 600 to 1000 nm. If the wavelength is less than 600 nm, the laser wavelength is short and does not penetrate deeply into the living tissue, and as a result, only photothermal treatment can be performed near the skin. If the wavelength is larger than 1000 nm, interference due to absorption of excess water existing in the living body increases, and thus, it is not preferable. The irradiation of the light may be performed percutaneously. Further, the irradiation of the light may be performed by a lamp or a laser.

(28) According to the present invention, the composition for photothermal therapy comprising carbon nanotubes coated with dextran is absorbed only into desired target cells, i.e., inflammatory cells to cause thermotherapeutic action through light irradiated from an external light source, while not damaging cells except for inflammatory cells. Accordingly, the composition for photothermal therapy according to the present invention has advantages of minimizing side effects and maximizing therapeutic effects.

(29) Hereinafter, various Examples are provided to help in understanding of the present invention. The following Examples are provided only for the purpose of easier understanding of the invention, but the scope of the present invention is not limited to the following Examples.

EXAMPLES

Example 1. Preparation of SWNT Coated with Dextran

(30) 40 to 80 mg of HiPCO as SWNT was dispersed in a 1% phenoxylated dextran (a molecular weight of dextran is 40 to 170 kDa) aqueous solution containing 14% phenoxy groups using a ultrasonic disperser (10 W, 1 hour), and then non-dispersed carbon nanotube bundles, catalysts, and the like were removed by using a bench top centrifuge (16,168 g) to prepare SWNT coated with dextran.

EXPERIMENTAL EXAMPLES

Experimental Example 1. Verification of Thermal Energy Emission Behavior According to Concentration of Dextran-Coated SWNT

(31) While light of an NIR laser (wavelength=808 nm) was irradiated to 0.1 mg/ml, 0.01 mg/ml and 0.001 mg/ml of the dextran-coated SWNT prepared in Example 1 for 10 minutes, respectively, changes in temperature were observed. The results were illustrated in FIG. 1.

(32) Referring to FIG. 1, it was observed that while light energy was converted into thermal energy, the temperature was increased and it was verified that the temperature was decreased after the laser was turned off. As a result, it was verified that the dextran-coated SWNT prepared in Example 1 had an effect of photothermal therapy only when the NIR laser was irradiated. Also, the temperature was increased to a maximum of 60 C. at a concentration of 0.1 mg/ml, but the increased range of the temperature was less than 35 C. at a concentration of 0.01 mg/ml, and as a result, there was a difference in the maximum temperature range depending on the concentration.

Experimental Example 2. Verification of Cytotoxicity of Dextran-Coated SWNT

(33) In order to determine cytotoxicity of the dextran-coated SWNT prepared in Example 1, an MTT assay to verify cell viability was performed.

(34) Raw 264.7 was used as a cell line, the number of cells was determined by a hemocytometer, and then the same amount of cells was seeded in each well of a 96-well plate. The composition was treated in each well at concentrations of 10-8, 10-7, 10-6, 10-5, 10-4, 10-3, 10-2, 10-1, and 100 and cultured at 37 C. for 24 hours to induce uptake to cells. The supernatant of each well was removed and an MTT solution was added to the wells. The MTT solution was dissolved with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) dissolved with 2 mg per PBS 1 ml, filtrated by a filter of 0.22 m, stored in a 4 C. dark condition, and used. The cell line was cultured for 4 hours under a 37 C. dark condition after treatment of the MTT solution. Next, the supernatant was removed and DMSO was added, and after shaking for 10 minutes, the number of viable cells was measured at a wavelength of 540 nm using an ELISA device. As a control, the cell line was cultured in the same manner in the wells treated with only dextran at concentrations of 10-8, 10-7, 10-6, 10-5, 10-4, 10-3, 10-2, 10-1, and 100 and then the MTT assay was performed, and the results were illustrated in FIG. 2.

(35) Referring to FIG. 2, as a control according to the present invention, even in a group treated with only dextran and a group treated with the dextran-coated SWNT according to the present invention, 80% or more of cell viability was shown. Accordingly, it was verified that the dextran-coated SWNT according to the present invention did not have cytotoxicity.

Experimental Example 3. Verification of Target-Cell Specificity of Dextran-Coated SWNT

(36) (1) Verification of Cell Uptake of Dextran-Coated SWNT

(37) In order to verify whether the dextran-coated SWNT prepared by Example 1 has target specificity, the dextran-coated SWNT was treated to the cell line for 24 hours to induce uptake to cells. As the cell line, a human fibroblast cell line NUFF1 and a mouse macrophage cell line Raw264.7 were used, and after 24 hours of treatment, UV was irradiated. Through FIG. 3, it was verified that the dextran-coated SWNT had a peak difference depending on the cells. Also, through FIG. 4, it was verified that the dextran-coated SWNT was stably uptaken in the Raw264.7 cell line.

(38) (2) Verification of Proper Concentration of Dextran-Coated SWNT

(39) Serial dilution of the concentration of 0.1 mg/ml of the dextran-coated SWNT by was performed in the Raw264.7 cell line for 24 hours and then the cell killing result by the NIR laser irradiation (wavelength: 808 nm) was verified. The results were illustrated in FIG. 5.

(40) Referring to FIG. 5, in the group treated with the dextran-coated SWNT at a concentration of 0.1 mg/ml, cell death also occurred even in areas other than the area irradiated with the laser, but when the concentration of the dextran-coated SWNT of 0.05 mg/ml was treated, cell death occurred only in the area irradiated with the laser. On the other hand, when the concentration of the dextran-coated SWNT was less than 0.05 mg/ml, it was verified that the cell killing effect was weak.

(41) (3) Verification of Target-Specific Cell Killing Effect of Dextran-Coated SWNT

(42) 0.05 mg/ml of the dextran-coated SWNT prepared by Example 1 was treated in Raw264.7 and NUFF1 for 24 hours and then irradiated with an NIR laser (wavelength: 808 nm). The laser-irradiated cells were stained with calcein AM, a dye that was colored by the enzymatic action of living cells, and EthD-1, a dye that was colored by binding to nucleic acid of dead cells with damaged cell membranes, and observed with a fluorescence microscope. The results were illustrated in FIG. 6. Referring to FIG. 6, it was verified that the NUFF1 was not affected by the laser irradiation treatment, but the Raw264.7, the target cells, had cell death in the laser irradiated area.

(43) On the other hand, the result obtained when the Raw264.7 cell line was irradiated with only the NIR laser was compared with the result obtained when the Raw264.7 cell line treated with the dextran-coated SWNT was irradiated with the NIR laser irradiation. The results were illustrated in FIG. 7. Referring to FIG. 7, when the Raw264.7 cell line was irradiated with only the NIR laser, it was verified that the cell death did not occur.

(44) For now, the present invention has been described with reference to the exemplary embodiments. It is understood to those skilled in the art that the present invention may be implemented as a modified form without departing from an essential characteristic of the present invention. Therefore, the disclosed exemplary embodiments should be considered from not a limitative viewpoint but an explanatory viewpoint. The scope of the present invention is described in not the above description but the appended claims, and it should be analyzed that all differences within the scope equivalent thereto are included in the present invention.